Finally, analyses of the data from Cancer Therapeutics Response Portal43 revealed that KEAP1 mutant NSCLC cells exhibit more resistance to class 2 FINs (RSL3, ML162, and ML210), but not to FIN56, than do KEAP1 WT NSCLC cells (Supplementary Fig. 2k–n). The gene discussed is KEAP1; the disease is cancer.